bioRxivCancer Biology
Identification of Subsets of Genetic Alterations in KRAS-mutant Lung Cancer using Association Rule Mining
Abstract
BackgroundLung cancer is the leading cause of all cancer death accounting for 1 out of 4 cancer-related death in both men and women. KRAS mutations occur in ~ 25% of patients with lung cancer, and the presence of these mutations is associated with poor prognosis. Efforts to directly target KRAS or associated downstream MAPK or the PI3K/AKT/mTOR pathways have seen little or no benefits. One probable reason for the lack of progress in targeting KRAS-mutant tumors is the co-occurrence of other cell survival pathways and mechanisms.\n\nMethod and resultsTo identify other potential cell survival pathways in subsets of KRAS-mutant tumors, I performed unsupervised machine learning on somatic mutations in metastatic lung cancer from 725 patient samples. I identified 67 other genes that were mutated in at least 10% of the samples with KRAS alterations. This gene list was enriched with genes involved in the MAPK, AKT and STAT3 pathways, cell-cell adhesion, DNA repair, chromatin remodeling, and the Wnt/beta-catenin pathway. I also identified 160 overlapping subsets of 3 or more genes that code for oncogenic or oncosuppressive proteins that were mutated in at least 10% of KRAS-mutant tumors.\n\nConclusionsIn this study, I identified genes that are co-mutated in KRAS-mutant lung cancer. I also identify subpopulations of KRAS-mutant lung cancer based on the set of genes that were also altered in the tumor samples. The design of research models that captures these subsets of KRAS-mutant tumors would enhance our understanding of the disease and facilitate personalized treatment for lung cancer patients with KRAS alterations.
- organism: human
- assay: whole-exome sequencing
- research focus: clustering
- approach: machine learning (classical)
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growth
R. Tang, E. G. Shuldiner, … M. M. Winslow·bioRxiv·Jul 8, 2021
- Effectors and potential targets selectively upregulated in human KRAS mutant lung adenocarcinomas
Jinyu Li, Raffaella Sordella, Scott Powers·bioRxiv·Jun 4, 2016
- Unveiling a Potential Prognostic Biomarker in KRAS-Mutant Lung Adenocarcinoma Using Weighted Gene Co-Expression Network Analysis
Yasmeen Dodin·bioRxiv·Jul 31, 2023
- RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
Alexander J. Pfeil, Tom Zhang, … Romel Somwar·Clinical Cancer ResearchPeer-reviewed·Jan 16, 2026
- SMARCA4 Mutations in KRAS-mutant Lung Adenocarcinoma: A Multi-cohort Analysis
Liang Liu, Tamjeed Ahmed, … Wei Zhang·Molecular OncologyPeer-reviewed·Oct 26, 2020
- Mutant KRAS dosage contributes to heterogeneity in lung cancer therapeutic response
Alice T. Browne, Chris McCann, … Emma M. Kerr·bioRxiv·May 9, 2026